We next tested imatinib that primarily targets the PDGFR signaling, which was approved for treating chronic myeloid leukemia by targeting BCR/ABL and treating gastrointestinal stromal tumor. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.